SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy.

Ridgley, LA; Caron, J; Dalgleish, A; Bodman-Smith, M (2023) Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy. Front Immunol, 13. p. 1065495. ISSN 1664-3224 https://doi.org/10.3389/fimmu.2022.1065495
SGUL Authors: Bodman-Smith, Mark Duncan

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (3MB) | Preview
[img]
Preview
Image (JPEG) (Supplementary Figure 1) Published Version
Available under License Creative Commons Attribution.

Download (325kB) | Preview
[img]
Preview
Image (JPEG) (Supplementary Figure 2) Published Version
Available under License Creative Commons Attribution.

Download (307kB) | Preview
[img]
Preview
Image (JPEG) (Supplementary Figure 3) Published Version
Available under License Creative Commons Attribution.

Download (223kB) | Preview
[img]
Preview
Image (JPEG) (Supplementary Figure 4) Published Version
Available under License Creative Commons Attribution.

Download (236kB) | Preview

Abstract

OBJECTIVES: Vγ9Vδ2 T-cells are a subset of T-cells with a crucial role in immunosurveillance which can be activated and expanded by multiple means to stimulate effector responses. Little is known about the expression of checkpoint molecules on this cell population and whether the ligation of these molecules can regulate their activity. The aim of this study was to assess the expression of both activatory and inhibitory receptors on Vγ9Vδ2 T-cells to assess potential avenues of regulation to target with immunotherapy. METHODS: Expression of various activatory and inhibitory receptors was assessed on Vγ9Vδ2 T-cells by flow cytometry following activation and expansion using zoledronic acid (ZA) and Bacillus Calmette-Guérin (BCG). Expression of these markers and production of effector molecules was also examined following co-culture with various tumour cell targets. The effect of immune checkpoint blockade on Vγ9Vδ2 T-cells was also explored. RESULTS: Vγ9Vδ2 T-cells expressed high levels of activatory markers both at baseline and following stimulation. Vγ9Vδ2 T-cells expressed variable levels of inhibitory checkpoint receptors with many being upregulated following stimulation. Expression of these markers is further modulated upon co-culture with tumour cells with changes reflecting activation and effector functions. Despite their high expression of inhibitory receptors when cultured with tumour cells expressing cognate ligands there was no effect on Vδ2+ T-cell cytotoxic capacity or cytokine production with immune checkpoint blockade. CONCLUSIONS: Our work suggests the expression of checkpoint receptors present on Vγ9Vδ2 T-cells which may provide a mechanism with the potential to be utilised by tumour cells to subvert Vγ9Vδ2 T-cell cytotoxicity. This work suggests important candidates for blockade by ICI therapy in order to increase the successful use of Vγ9Vδ2 T-cells in immunotherapy.

Item Type: Article
Additional Information: Copyright © 2023 Ridgley, Caron, Dalgleish and Bodman-Smith. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Keywords: BCG, NKG2A, Vγ9Vδ2 T-cell, ZA, immune checkpoint inhibitor, Humans, T-Lymphocytes, Immune Checkpoint Inhibitors, Receptors, Antigen, T-Cell, gamma-delta, Lymphocyte Activation, Immunotherapy, Neoplasms, T-Lymphocytes, Humans, Neoplasms, Receptors, Antigen, T-Cell, gamma-delta, Immunotherapy, Lymphocyte Activation, Immune Checkpoint Inhibitors, V gamma 9V delta 2 T-cell, BCG, ZA, immune checkpoint inhibitor, NKG2A, 1107 Immunology, 1108 Medical Microbiology
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Front Immunol
ISSN: 1664-3224
Language: eng
Dates:
DateEvent
13 January 2023Published
16 December 2022Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
1080343Institute for Cancer Vaccines and Immunotherapyhttp://dx.doi.org/10.13039/501100022585
PubMed ID: 36713444
Web of Science ID: WOS:000922995100001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/115217
Publisher's version: https://doi.org/10.3389/fimmu.2022.1065495

Actions (login required)

Edit Item Edit Item